|
Prevention of Early Readmission in Elderly Congestive Heart Failure Patients Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Prevention of Early Readmission in Elderly Congestive Heart Failure Patients conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Prevention of Early Readmission in Elderly Congestive Heart Failure Patients Clinical research trials and Prevention of Early Readmission in Elderly Congestive Heart Failure Patients medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Prevention of Early Readmission in Elderly Congestive Heart Failure Patients. Prevention of Early Readmission in Elderly Congestive Heart Failure Patients Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Prevention of Early Readmission in Elderly Congestive Heart Failure Patients clinical trial. Test subjects typically obtain the finest healthcare available for their Prevention of Early Readmission in Elderly Congestive Heart Failure Patients condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Prevention of Early Readmission in Elderly Congestive Heart Failure Patients  Prevention of Early Readmission in Elderly Congestive Heart Failure Patients
Prevention of Early Readmission in Elderly Congestive Heart Failure Patients
For Condition: Cardiovascular Diseases,Heart Diseases,Heart Failure, Congestive,Heart Failure
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To assess the impact of a multidisciplinary treatment program on three-month readmission-free survival in elderly congestive heart failure patients.
Details: BACKGROUND: The prevalence of congestive heart failure increases progressively with advancing age, and congestive heart failure is a major cause of mortality, morbidity, and diminished quality of life in the elderly. Not only is congestive heart failure the most common cardiovascular indication for hospitalization in patients 65 years or older, but frequent repetitive hospitalizations, occurring in 30-50 percent of patients within three to six months of initial discharge, create an imposing cost burden in caring for these patients. A pilot study conducted at the grantee institution has shown that elderly congestive heart failure patients at risk for early readmission can be identified at the time of initial hospitalization, that up to 50 percent of readmissions are potentially preventable, and that a non-pharmacologic treatment strategy consisting of patient education, medication analysis, discharge planning, and enhanced follow-up is feasible and may reduce readmissions by 30 to 50 percent. DESIGN NARRATIVE: In the feasibility study, patients were randomly assigned to receive intervention or standard care over a four year period. Patients were stratified into readmission risk categories of high or moderate based on the presence of four independent risk factors for readmission defined in a prior study at Jewish Hospital in St. Louis. The risk factors included: four or more prior hospitalizations within the preceding five-year interval, previous history of congestive heart failure, hypocholesterolemia, and right bundle-branch block on the admitting electrocardiogram. The study intervention consisted of individualized patient education using teaching materials specifically designed for the study; a careful review of medications with specific recommendations designed to eliminate unnecessary drugs, decrease the number of dosing intervals, improve compliance, and minimize side effects; early discharge planning; and enhanced post-discharge follow-up. The primary endpoints were rehospitalization within 90 days after initial hospital discharge and the cumulative number of days hospitalized during follow-up. Principal secondary endpoints included analyses of the effect of the study intervention on compliance with prescribed medications, dietary sodium intake, incidence of adverse drug reactions, patient knowledge and understanding of congestive heart failure, patient-assessed quality of life, and the overall cost of medical care. In the full-scale trial, 140 patients were assigned to the control group which received all standard treatments and services ordered by their physicians. A total of 142 patients were assigned to the treatment group which received intensive education about congestive heart failure and its treatment by an experienced cardiovascular research nurse, using a teaching booklet developed by study investigators for geriatric patients with heart failure. Treatment group patients also received individualized dietary assessment and instruction given by a registered dietitian; consultation with social-service personnel to facilitate discharge planning and care after discharge; an analysis of medications by a geriatric cardiologist who made specific recommendations to eliminate unnecessary medications and simplify the overall regimen; and intensive follow-up after discharge. The goals of follow-up were to reinforce the patient's education, ensure compliance with medications and diet, and identify recurrent symptoms amenable to treatment on an outpatient basis. The primary outcome measure was survival for 90 days without hospital readmission. Secondary endpoints included the number of readmissions for any cause, the number of readmissions for congestive heart failure, the cumulative number of days of hospitalization during follow-up, quality-of-life scores, and the overall cost of medical care.
Eligibility:
Study Type: Interventional, Prevention, Randomized
Minimum Age/Maximum Age: 70 Years/
Genders: Both
Protocol Entry Criteria: Men and women, ages 70 or older, with documented congestive heart failure.
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 64;
Study Start Date: April 1990
Record last reviewed: September 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000475
Other Heart Failure Studies:
1. Increased Physical Activity in African-American Women
2. Gubbio Study Five-year Follow-up: Lithium Countertransport, Blood Pressure, and Other Variables
3. Trial of Antihypertensive Intervention Management
4. Anger and Cardiovascular Risk in Urban Youth
5. Epidemiology of Symptomatic Arrhythmias
Related Studies:
Other Heart Failure Clinical Trials
Other Clinical Trials
Other Clinical Trials
Prevention of Early Readmission in Elderly Congestive Heart Failure Patients
|
|
|
|
|
|
|
|
